Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunosuppressantit - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopic - muut dermatologiset valmisteet - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

viatris oy - pimecrolimus - emulsiovoide - 10 mg/g - pimekrolimuusi

Euroopan unioni - suomi - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressantit - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

teva b.v. - desonide - voide - 0.1 % - desonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

leo pharma a/s - hydrocortisone acetate, fusidic acid - emulsiovoide - hydrokortisoni ja antibiootit

Suomi - suomi - Fimea (Suomen lääkevirasto)

bayer oy - methylprednisoloni aceponas - emulsio iholle - 0.1 % - metyyliprednisoloniaseponaatti

Suomi - suomi - Fimea (Suomen lääkevirasto)

glenmark arzneimittel gmbh - beclometasone dipropionate - inhalaatiosumute, liuos - 50 mikrog/annos - beklometasoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

glenmark arzneimittel gmbh - beclometasone dipropionate - inhalaatiosumute, liuos - 100 mikrog/annos - beklometasoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

glenmark arzneimittel gmbh - beclometasone dipropionate - inhalaatiosumute, liuos - 200 mikrog/annos - beklometasoni